UNSPSC 51413601: Cinepazet

This classification denotes a vasodilating agent with the molecular formula C20H28N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0LC95WWE9Q, chemically known as 4-(1- oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-1-piperazineacetic acid, ethyl ester but generally known as cinepazet, which bears US NIH Compound Identifier 6436156. European Medicines Agency schedules Cinepazet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06291MIG. The term CINEPAZET is an International Non-Proprietary Name.

UNSPSC 51413601 Cinepazet, a Commodity code, represents pharmaceutical products that state and local governments procure for emergency medical services, institutional health programs, and pharmacy benefit initiatives. Recent solicitations show state and local buyers acquiring emergency life support medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription programs. Issuing bodies include municipal fire departments and emergency services (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances serving state and local facilities (Minnesota Multistate Cooperative Purchasing Alliance). The code attracts both emergency-response procurement and broader institutional pharmacy procurement vehicles.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's Purchasing Department issued Invitation for Bids (IFB) 26P00188 on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with bids due April 8, 2026, and an estimated contract value of $40,000; the procurement includes a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, contract effective date, requiring vendors to maintain relationships with specified authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on direct-contracting capacity outside traditional PBM and GPO channels.